{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,17]],"date-time":"2026-10-17T00:11:03Z","timestamp":1792195863929,"version":"4.4.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,2,1]],"date-time":"2025-02-01T00:00:00Z","timestamp":1738368000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,12,7]],"date-time":"2024-12-07T00:00:00Z","timestamp":1733529600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["thelancet.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["eBioMedicine"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1016\/j.ebiom.2024.105515","type":"journal-article","created":{"date-parts":[[2025,1,13]],"date-time":"2025-01-13T15:18:30Z","timestamp":1736781510000},"page":"105515","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["ATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A\u22170201"],"prefix":"10.1016","volume":"112","author":[{"given":"Li","family":"Yuan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sini","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yixiang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lin","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xue","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhijie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianchun","family":"Duan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Zhong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanhua","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7861-6812","authenticated-orcid":false,"given":"Lihui","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Boyang","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kailun","family":"Fei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zheng","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yufeng","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-1017-1166","authenticated-orcid":false,"given":"DanMing","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wei","family":"Zhuang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinsong","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zixiao","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hua","family":"Bai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5602-0487","authenticated-orcid":false,"given":"Jie","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ebiom.2024.105515_bib1","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.ebiom.2024.105515_bib2","doi-asserted-by":"crossref","first-page":"69","DOI":"10.21037\/tlcr.2018.01.16","article-title":"Current standards for clinical management of small cell lung cancer","volume":"7","author":"Farago","year":"2018","journal-title":"Transl Lung Cancer Res"},{"issue":"23","key":"10.1016\/j.ebiom.2024.105515_bib3","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.ebiom.2024.105515_bib4","doi-asserted-by":"crossref","first-page":"3740","DOI":"10.1200\/JCO.2016.67.6601","article-title":"Phase III randomized trial of ipilimumab plus etoposide and platinum versus placebo plus etoposide and platinum in extensive-stage small-cell lung cancer","volume":"34","author":"Reck","year":"2016","journal-title":"J\u00a0Clin Oncol"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105515_bib5","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1200\/JCO.20.01055","article-title":"Updated overall survival and PD-L1 subgroup analysis of patients with extensive-stage small-cell lung cancer treated with Atezolizumab, carboplatin, and etoposide (IMpower133)","volume":"39","author":"Liu","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105515_bib6","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S1470-2045(20)30539-8","article-title":"Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomized, controlled, open-label, phase 3 trial","volume":"22","author":"Goldman","year":"2021","journal-title":"Lancet Oncol"},{"issue":"6","key":"10.1016\/j.ebiom.2024.105515_bib7","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1016\/S1470-2045(22)00224-8","article-title":"Adebrelimab or placebo plus carboplatin and etoposide as first-line treatment for extensive-stage small-cell lung cancer (CAPSTONE-1): a multicentre, randomized, double-blind, placebo-controlled, phase 3 trial","volume":"23","author":"Wang","year":"2022","journal-title":"Lancet Oncol"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105515_bib8","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1038\/s41392-022-01150-4","article-title":"Single-cell transcriptomic profiling reveals the tumour heterogeneity of small-cell lung cancer","volume":"7","author":"Tian","year":"2022","journal-title":"Signal Transduct Target Ther"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105515_bib9","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1038\/s41568-019-0133-9","article-title":"Molecular subtypes of small cell lung cancer: a synthesis of human and mouse model data","volume":"19","author":"Rudin","year":"2019","journal-title":"Nat Rev Cancer"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105515_bib10","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1016\/j.jtho.2021.08.763","article-title":"Molecular subtypes of primary SCLC tumors and their associations with neuroendocrine and therapeutic markers","volume":"17","author":"Qu","year":"2022","journal-title":"J Thorac Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105515_bib11","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.ccell.2020.12.014","article-title":"Patterns of transcription factor programs and immune pathway activation define four major subtypes of SCLC with distinct therapeutic vulnerabilities","volume":"39","author":"Gay","year":"2021","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105515_bib12","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1016\/j.jtho.2020.11.006","article-title":"YAP1 expression in SCLC defines a distinct subtype with T-cell-inflamed phenotype","volume":"16","author":"Owonikoko","year":"2021","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.ebiom.2024.105515_bib13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1186\/s13045-023-01492-8","article-title":"Challenges and new technologies in adoptive cell therapy","volume":"16","author":"Zhang","year":"2023","journal-title":"J\u00a0Hematol Oncol"},{"key":"10.1016\/j.ebiom.2024.105515_bib14","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40164-024-00504-8","article-title":"Novel insights into TCR-T cell therapy in solid neoplasms: optimizing adoptive immunotherapy","volume":"13","author":"Shao","year":"2024","journal-title":"Exp Hematol Oncol"},{"key":"10.1016\/j.ebiom.2024.105515_bib15","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.4049\/jimmunol.1700236","article-title":"Comparison of T Cell activities mediated by human TCRs and CARs that use the same recognition domains","volume":"200","author":"Harris","year":"2018","journal-title":"J\u00a0Immunol"},{"key":"10.1016\/j.ebiom.2024.105515_bib16","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/s41421-018-0066-6","article-title":"A\u00a0novel antibodyTCR (AbTCR) platform combines Fab-based antigen recognition with gamma\/delta-TCR signaling to facilitate T-cell cytotoxicity with low cytokine release","volume":"4","author":"Xu","year":"2018","journal-title":"Cell Discov"},{"key":"10.1016\/j.ebiom.2024.105515_bib17","doi-asserted-by":"crossref","DOI":"10.1016\/j.canlet.2022.215840","article-title":"Neoantigen-targeted TCR-T cell therapy for solid tumours: how far from clinical application","volume":"546","author":"Xu","year":"2022","journal-title":"Cancer Lett"},{"issue":"7","key":"10.1016\/j.ebiom.2024.105515_bib18","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1158\/2159-8290.CD-22-0620","article-title":"Integrative analysis of a large real-world cohort of small cell lung cancer identifies distinct genetic subtypes and insights into histologic transformation","volume":"13","author":"Sivakumar","year":"2023","journal-title":"Cancer Discov"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105515_bib19","doi-asserted-by":"crossref","first-page":"349","DOI":"10.18632\/oncoscience.37","article-title":"A\u00a0novel cohort of cancer-testis biomarker genes revealed through meta-analysis of clinical data sets","volume":"1","author":"Sammut","year":"2014","journal-title":"Oncoscience"},{"key":"10.1016\/j.ebiom.2024.105515_bib20","doi-asserted-by":"crossref","first-page":"3278","DOI":"10.1073\/pnas.73.9.3278","article-title":"Cell surface antigens of human malignant melanoma: mixed hemadsorption assays for humoral immunity to cultured autologous melanoma cells","volume":"73","author":"Carey","year":"1976","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.ebiom.2024.105515_bib21","first-page":"1","article-title":"The cancer\/testis genes: review, standardization, and commentary","volume":"4","author":"Scanlan","year":"2004","journal-title":"Cancer Immun"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105515_bib22","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1038\/s41591-022-02128-z","article-title":"Autologous T cell therapy for MAGE-A4+ solid cancers in HLA-A\u221702+ patients: a phase 1 trial","volume":"29","author":"Hong","year":"2023","journal-title":"Nat Med"},{"issue":"8","key":"10.1016\/j.ebiom.2024.105515_bib23","article-title":"Phase 1 clinical trial to assess safety and efficacy of NY-ESO-1-specific TCR T cells in HLA-A\u221702:01 patients with advanced soft tissue sarcoma","volume":"4","author":"Pan","year":"2023","journal-title":"Cell Rep Med"},{"issue":"20","key":"10.1016\/j.ebiom.2024.105515_bib24","doi-asserted-by":"crossref","first-page":"5606","DOI":"10.1158\/1078-0432.CCR-12-0505","article-title":"A\u00a0comparative and integrative approach identifies ATPase family, AAA domain containing 2 as a likely driver of cell proliferation in lung adenocarcinoma","volume":"18","author":"Fouret","year":"2012","journal-title":"Clin Cancer Res"},{"issue":"39","key":"10.1016\/j.ebiom.2024.105515_bib25","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.6152","article-title":"Suppression of ATAD2 inhibits hepatocellular carcinoma progression through activation of p53-and p38-mediated apoptotic signaling","volume":"6","author":"Lu","year":"2015","journal-title":"Oncotarget"},{"issue":"2","key":"10.1016\/j.ebiom.2024.105515_bib26","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/nrd4204","article-title":"PI3K and cancer: lessons, challenges and opportunities","volume":"13","author":"Fruman","year":"2014","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105515_bib27","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1038\/ncomms5750","article-title":"Division of labour between Myc and G1 cyclins in cell cycle commitment and pace control","volume":"5","author":"Dong","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.ebiom.2024.105515_bib28","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.ceb.2015.06.004","article-title":"Modes of cancer cell invasion and the role of the microenvironment","volume":"36","author":"Clark","year":"2015","journal-title":"Curr Opin Cell Biol"},{"issue":"5","key":"10.1016\/j.ebiom.2024.105515_bib29","doi-asserted-by":"crossref","first-page":"1087","DOI":"10.3390\/ijms20051087","article-title":"Steroid receptor signallings as targets for resveratrol actions in breast and prostate cancer","volume":"20","author":"De Amicis","year":"2019","journal-title":"Int J Mol Sci"},{"issue":"43","key":"10.1016\/j.ebiom.2024.105515_bib30","doi-asserted-by":"crossref","DOI":"10.18632\/oncotarget.11855","article-title":"ATAD2 is an epigenetic reader of newly synthesized histone marks during DNA replication","volume":"7","author":"Koo","year":"2016","journal-title":"Oncotarget"},{"issue":"6871","key":"10.1016\/j.ebiom.2024.105515_bib31","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1038\/415530a","article-title":"Gene expression profiling predicts clinical outcome of breast cancer","volume":"415","author":"van\u2019t Veer","year":"2002","journal-title":"Nature"},{"issue":"8","key":"10.1016\/j.ebiom.2024.105515_bib32","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1007\/s12094-015-1430-8","article-title":"ATAD2 is overexpressed in gastric cancer and serves as an independent poor prognostic biomarker","volume":"18","author":"Zhang","year":"2016","journal-title":"Clin Transl Oncol"},{"issue":"3","key":"10.1016\/j.ebiom.2024.105515_bib33","first-page":"3489","article-title":"ATAD2 is associated with malignant characteristics of pancreatic cancer cells","volume":"17","author":"Liu","year":"2019","journal-title":"Oncol Lett"},{"issue":"1","key":"10.1016\/j.ebiom.2024.105515_bib34","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1080\/14728222.2018.1406921","article-title":"ATAD2 in cancer: a pharmacologically challenging but tractable target","volume":"22","author":"Hussain","year":"2018","journal-title":"Expert Opin Ther Targets"},{"issue":"12","key":"10.1016\/j.ebiom.2024.105515_bib35","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1002\/1878-0261.13474","article-title":"Expression of cancer-testis antigens in the immune microenvironment of non-small cell lung cancer","volume":"17","author":"Hikmet","year":"2023","journal-title":"Mol Oncol"},{"key":"10.1016\/j.ebiom.2024.105515_bib36","doi-asserted-by":"crossref","first-page":"615e25","DOI":"10.1038\/nrc1669","article-title":"Cancer\/testis antigens, gametogenesis and cancer","volume":"5","author":"Simpson","year":"2005","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ebiom.2024.105515_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/nar\/gkn673","article-title":"CTdatabase: a knowledge-base of high-throughput and curated data on cancer-testis antigens","volume":"37","author":"Almeida","year":"2009","journal-title":"Nucleic Acids Res"},{"issue":"8","key":"10.1016\/j.ebiom.2024.105515_bib38","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.1016\/j.jtho.2022.05.014","article-title":"Targeting lysine-specific demethylase 1 rescues major histocompatibility complex class I antigen presentation and overcomes programmed death-ligand 1 blockade resistance in SCLC","volume":"17","author":"Nguyen","year":"2022","journal-title":"J\u00a0Thorac Oncol"},{"issue":"9","key":"10.1016\/j.ebiom.2024.105515_bib39","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1016\/j.jtho.2023.05.008","article-title":"Clinical benefit from immunotherapy in patients with SCLC is associated with tumour capacity for antigen presentation","volume":"18","author":"Rudin","year":"2023","journal-title":"J\u00a0Thorac Oncol"},{"key":"10.1016\/j.ebiom.2024.105515_bib40","doi-asserted-by":"crossref","first-page":"2697","DOI":"10.3389\/fimmu.2018.02697","article-title":"Specific MHC-I peptides are induced using PROTACs","volume":"9","author":"Jensen","year":"2018","journal-title":"Front Immunol"},{"key":"10.1016\/j.ebiom.2024.105515_bib41","doi-asserted-by":"crossref","DOI":"10.1016\/j.mcpro.2021.100143","article-title":"Immunopeptidogenomics: harnessing RNA-seq to illuminate the dark immunopeptidome","volume":"20","author":"Scull","year":"2021","journal-title":"Mol Cell Proteomics"},{"key":"10.1016\/j.ebiom.2024.105515_bib42","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.molimm.2020.04.008","article-title":"In-depth mining of the immunopeptidome of an acute myeloid leukemia cell line using complementary ligand enrichment and data acquisition strategies","volume":"123","author":"Pandey","year":"2020","journal-title":"Mol Immunol"},{"issue":"16","key":"10.1016\/j.ebiom.2024.105515_bib43","doi-asserted-by":"crossref","first-page":"3975","DOI":"10.3390\/cancers14163975","article-title":"Multi-Omic analysis of two common P53 mutations: proteins regulated by mutated P53 as potential targets for immunotherapy","volume":"14","author":"Vadakekolathu","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"19","key":"10.1016\/j.ebiom.2024.105515_bib44","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.141264","article-title":"Solving an MHC allele-specific bias in the reported immunopeptidome","volume":"5","author":"Klatt","year":"2020","journal-title":"JCI Insight"},{"issue":"9","key":"10.1016\/j.ebiom.2024.105515_bib45","article-title":"Subtype of SCLC is an intrinsic and persistent feature through systemic treatment","volume":"4","author":"Lo","year":"2023","journal-title":"JTO Clin Res Rep"},{"issue":"12","key":"10.1016\/j.ebiom.2024.105515_bib46","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1158\/1541-7786.MCR-20-1006","article-title":"Sox 2 is an oncogenic driver of small-cell lung cancer and promotes the classic neuroendocrine subtype","volume":"19","author":"Voigt","year":"2021","journal-title":"Mol Cancer Res"}],"container-title":["eBioMedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424005516?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2352396424005516?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,3,13]],"date-time":"2025-03-13T23:57:05Z","timestamp":1741910225000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2352396424005516"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,2]]},"references-count":46,"alternative-id":["S2352396424005516"],"URL":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105515","relation":{},"ISSN":["2352-3964"],"issn-type":[{"value":"2352-3964","type":"print"}],"subject":[],"published":{"date-parts":[[2025,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"ATAD2 is a potential immunotherapy target for patients with small cell lung cancer harboring HLA-A\u22170201","name":"articletitle","label":"Article Title"},{"value":"eBioMedicine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ebiom.2024.105515","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"105515"}}